Author Archives: Jan Paschal

Iambic Therapeutics(IAM) priced its IPO at $16.00 – the mid-point – and sold 9.38 million shares – the number in the prospectus – to raise $150 million on Wednesday night, Oct. 14. The Phase I cancer biotech’s stock edged higher in its NASDAQ debut – opening at $16.15 shortly after noon EDT on Thursday, Oct. […]

Iambic Therapeutics (IAM Proposed) and City Therapeutics (CTY Proposed) are in the spotlight this week as the only two deals on the IPO Calendar so far. Both biotechs are set to go public in a year that’s seen a resurgence in the volume of biotech sector IPOs, compared with 2025. This week’s light IPO Calendar […]

City Therapeutics (CTY Proposed) unveiled its IPO’s terms early today – 9.72 million shares at a price range of $17.00 to $19.00 to raise $174.96 million, if priced at the $18.00 mid-point of its range, according to its S-1/A filing dated Oct. 9, 2026. This is a NASDAQ listing. (Please see our IPO Calendar for […]

TRex Bio (TRXB) priced its IPO at $14.00 – the low end of its range – and sold 8.33 million shares – the number in the prospectus – to raise $116.62 million on Thursday night, Oct. 8, 2026. Today –TRex Bio’s stock slipped 50 cents to open at $13.50 – in its NASDAQ debut at […]

Iambic Therapeutics (IAM Proposed), a biotech targeting breast cancer and lung cancer, unveiled the terms for its $150 million IPO early today and launched the deal for pricing next week. The company is offering 9.38 million shares at a price range of $15.00 to $17.00 to raise $150 million, if priced at the $16.00 mid-point […]

TRex Bio (TRXB Proposed), an Eli Lilly-backed biotech, unveiled the terms for its $125 million IPO early today: 8.33 million shares at a price range of $14.00 to $16.00 to raise $124.95 million, if priced at the $15.00 mid-point of its range, according to its S-1 filing dated Oct. 5, 2026. This is a NASDAQ  […]

Accelevation Holdings (ACCV) priced its IPO at $18.00 – $2.00 below range – and sold 30 million shares – the number of shares in the prospectus – to raise $540 million on Tuesday night, Sept. 29, 2026. Of the 30 million shares in the IPO, Accelevation offered 10 million shares and the selling stockholders (the […]

Oura (OURA Proposed), the maker of the Oura Ring, the world’s smallest smart ring, postponed its $2.1 billion IPO “despite strong demand, due to uncertainty in the IPO market,” the company said early today (Tuesday, Sept. 29, 2026). Oura’s IPO had been set to price tonight to trade tomorrow on the NASDAQ. Oura’s decision marks […]

Oura is creating some buzz to ring out September. It’s known for the Oura Ring, which it calls  “the world’s smallest smart ring.” Its software provides users with data on how their daily habits – diet, exercise, sleep and other metrics – affect their health. “It’s an always-on health intelligence platform on your finger,” Oura […]

ADARx Pharmaceuticals (ADRX) upsized its IPO at pricing to 26.25 million shares – up from 21.88 million shares in the prospectus –  and priced the IPO at $17.00 – the high end of its $15.00-to-$17.00 range – to raise $446.25 million on Thursday night, Sept. 24, 2026. At pricing, ADARx Pharmaceuticals (ADRX) had a market […]